UroGen’s shares drop 20% as the FDA raises concerns about the trial design for UGN-102 bladder cancer treatment.

As the FDA prepares for a busy Oncologic Drugs Advisory Committee meeting next week, an agency insider told BioSpace that ...

UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced financial results for ...

Immune checkpoint inhibitors have shown a survival benefit in patients with metastatic urothelial cancer, so investigators trialed neoadjuvant nivolumab and ipilimumab in patients with muscle-invasive ...

And if the drug – their combination gets approved with a single-agent mitomycin that stays in your bladder about four hours, then a single-arm trial in that setting with our formulation makes a ...

Post-cystoscopy imaging noted a right lateral anterior bladder mass demonstrating hyper-enhancement ... chemotherapy regimens are supported by strong data (cisplatin, 5FU/mitomycin C, gemcitabine) ...

Bladder Cancer Awareness Month highlights the importance of early detection and support for patients, emphasizing the disease's prevalence and potential fatality. Treatment strategies differ by ...